Neoplasms

Gland and Hormone Related Diseases

All Conditions

Thyroid Neoplasms

Thyroid Diseases

Endocrine System Diseases

Endocrine Gland Neoplasms

Head and Neck Neoplasms

patients who were pathologically (histologically) diagnosed as papillary carcinoma (PTC). They are in advanced stage and need systemic therapies. These patients may be unresectable, recurrent, persistent, or metastatic disease with RAI refractory or ineligible and need systemic therapies.

patients who were pathologically diagnosed as DTC other than PTC, which includes follicular carcinoma, Hurthle cell carcinoma, and poorly differentiated carcinoma. The patients are in advanced stage and need systemic therapies. These patients may be unresectable, recurrent, persistent, or metastatic disease with RAI refractory or ineligible and need systemic therapies.

patients who were pathologically diagnosed as medullary thyroid cancer (MTC) with persistent disease.

patients who were pathologically diagnosed as anaplastic thyroid cancer (ATC).

the patients who had performed large scale NGS oncopanel test previously and fulfil with the criteria in cohort A, B, C, or D.

The patients must meet all the inclusion criteria and none of the exclusion criteria in each cohort.

A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients

Yuchin Chang

Mei-Yueh Lee

Hueng-Yuan Shen

Chen-Yuan Lin

Chung-Jye Hung

Chia-Chi Lin

Jui-Yu Chen

Ren-Hua Yehn

Miaw-Jene Liou

Because one cancer type may harbor various genetic aberrations, it is not enough to check only one or a few genes for a patient to choose the adequate treatment. Because the advance in multiplex genomic testing, several NGS-based cancer-associated genetic panel tests (oncopanel) have been developed and used to identify the genetic alterations, particularly the actionable genes, in each patient. Large scale checks of oncopanel have been executed in US. The study showed the genetic alterations in various cancer types and 11% of the patients had further molecular targeted therapy based on the result of the oncopanel test. Similar program was also conducted in Japan. Moreover, the oncopanel tests have been implicated in their clinical practice and the cost was reimbursed by the government of Japan and Korea recently. Precision medicine and such personalized treatment is the trend of cancer treatment. The trend of such treatment patterns is also observed in Taiwan. The genetic background for cancer treatment may also be different among different areas and races. There is short of genetic alteration data in Taiwanese cancer patients. To understand the landscape of genetic aberrations of cancer in Taiwan, large scale survey of the cancer patients is indicated. investigators propose to evaluate the landscape of genetic aberrations in cancer patients via oncopaenl test and collect the clinical data of the patients. The result of the oncopanel test will be provided to patients and their attending physicians as reference for their further treatment. In addition, investigators want to correlate the clinical outcome with the genetic aberrations of the cancer patients in Taiwan. Thyroid cancers are divided into differentiated thyroid cancer (DTC), medullary and anaplastic carcinoma. The majority of the patients are DTC. Different from other cancer type, radioactive iodine (RAI) therapy is usually the main treatment for advanced DTC. Multitargeted kinase inhibitors are indicated for advanced DTC refractory to RAI therapy and advanced medullary thyroid cancer. For anaplastic thyroid cancer, the prognosis is poor in spite of chemotherapy or radiation therapy. BRAF or NTRK targeted therapies are suggested if the patients have these genetic aberrations. Thyroid cancer patients have various genetic aberrations, including BRAF, RAS, RET, NTRK and others. Various gene specific kinase inhibitors have been developed and demonstrated the efficacy for the treatment of advanced thyroid cancer in addition to current standard therapies. Thyroid cancer is a cancer type with high percentage of driver gene aberration, however the genetic landscape of thyroid cancer is not well understood in Taiwan. In the current study, investigators want to investigate the genetic aberrations of advanced thyroid cancers by performing the NGS oncopanel.

Cancer is the most common cause of death in Taiwan since 1982. The incidence of cancer is increasing worldwide, including Taiwan. Cancers in early stage can usually be treated by surgery with a good prognosis. However, the prognosis for recurrent, locally advanced or metastatic cancers is poor with a shorter survival. Systemic treatments are usually indicated for these patients. Chemotherapy is the mainstay for advanced cancer patients. However, the advances in the understanding of cancer biology and identification of targeted therapeutics not only increase the treatment strategies of cancer but also improve the survival and quality of life of the cancer patients. There are more and more molecularly targeted therapy developed and approved for the treatment of advanced cancer patients currently, which makes the beginning of precision cancer medicine. There are more and more treatments can be used based on the genetic aberrations of the cancers. Because one cancer type may harbor various genetic aberrations, it is not enough to check only one or a few genes for a patient to choose the adequate treatment. Because the advance in multiplex genomic testing, several NGS-based cancer-associated genetic panel tests (oncopanel) have been developed and used to identify the genetic alterations, particularly the actionable genes, in each patient. Large scale checks of oncopanel have been executed in US. The study showed the genetic alterations in various cancer types and 11% of the patients had further molecular targeted therapy based on the result of the oncopanel test. Similar program was also conducted in Japan. Moreover, the oncopanel tests have been implicated in their clinical practice and the cost was reimbursed by the government of Japan and Korea recently. Precision medicine and such personalized treatment is the trend of cancer treatment. The trend of such treatment patterns is also observed in Taiwan. The genetic background for cancer treatment may also be different among different areas and races. There is short of genetic alteration data in Taiwanese cancer patients. To understand the landscape of genetic aberrations of cancer in Taiwan, large scale survey of the cancer patients is indicated. investigators propose to evaluate the landscape of genetic aberrations in cancer patients via oncopaenl test and collect the clinical data of the patients. The result of the oncopanel test will be provided to patients and their attending physicians as reference for their further treatment. In addition, investigators want to correlate the clinical outcome with the genetic aberrations of the cancer patients in Taiwan. Thyroid cancers are divided into differentiated thyroid cancer (DTC), medullary and anaplastic carcinoma. The majority of the patients are DTC. Different from other cancer type, radioactive iodine (RAI) therapy is usually the main treatment for advanced DTC. Multitargeted kinase inhibitors are indicated for advanced DTC refractory to RAI therapy and advanced medullary thyroid cancer. For anaplastic thyroid cancer, the prognosis is poor in spite of chemotherapy or radiation therapy. BRAF or NTRK targeted therapies are suggested if the patients have these genetic aberrations. Thyroid cancer patients have various genetic aberrations, including BRAF, RAS, RET, NTRK and others. Various gene specific kinase inhibitors have been developed and demonstrated the efficacy for the treatment of advanced thyroid cancer in addition to current standard therapies. Thyroid cancer is a cancer type with high percentage of driver gene aberration, however the genetic landscape of thyroid cancer is not well understood in Taiwan. In the current study, investigators want to investigate the genetic aberrations of advanced thyroid cancers by performing the NGS oncopanel. Then investigators can understand the genetic aberrations of these patients in Taiwan and help search potential treatment targets for these patients.

1. One H\&E staining slide, and 10-18 tissue slides (5 um thickness) for cancer panel.
2. Details of Tests/Collaborative Test Unit:

   Testing will take place in a certified precision medicine laboratory.
3. Non-tumor Sample (Blood): Eight (8) ml of blood in EDTA tube will be collected from the participant

A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID)

National Health Research Institutes, Taiwan

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Symptoms and General Pathology

Immune System Diseases

Prostatic Neoplasms

Neoplasm Metastasis

Hypersensitivity

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Antineoplastic Agents

All Drugs and Chemicals

Reproductive Control Agents

Docetaxel

Leuprolide

Goserelin

Triptorelin Pamoate

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Hormonal

Contraceptive Agents

Contraceptive Agents, Female

Contraceptive Agents, Hormonal

abiraterone

enzalutamide

docetaxel

apalutamide

cabazitaxel

Radium-223

Lutetium-177

degarelix

goserelin

leuprorelin

triptorelin

Pfizer CT.gov Call Center

Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions:

* What are the demographic and clinical characteristics of metastatic prostate cancer patients?
* How are metastatic prostate cancer patients currently treated and how effective are these treatments?
* How does the development of castration-resistance affect patient outcomes?
* What is the economic burden of metastatic prostate cancer?

Male patients with cancer of the prostate.

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Demographical and clinical variables of patients will be summarized

Pfizer

Blood and Lymph Conditions

Rare Diseases

Syndrome

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Preleukemia

Myelodysplastic Syndromes

Neoplasms by Histologic Type

Hematologic Diseases

Bone Marrow Diseases

Precancerous Conditions

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Hartmut Döhner, Prof. Dr.

Armin Zebisch, Prof. Dr.

David Nachbaur, Prof. Dr.

Michael Girschikofsky, Dr.

Clemens Schmitt, Prof.

Bernd Hartmann, Dr.

Richard Greil, Prof. Dr.

Elisabeth Koller, Dr.

Manfred Welslau, Dr.

Daniel Schöndube, Dr.med.

Annette Dieing, Dr.

Maike De Wit, Prof. Dr. med.

Jörg Westermann, PD Dr.

Joerg-Christian Rath, Dr.

Stefan Lukic, Dr.

Roland Schroers, Prof. Dr.

Lino Teichmann, Dr.

Jürgen Krauter, Prof. Dr.

Bernd Hertenstein, Prof. Dr. med.

Helga Bernhard, Prof. Dr. med.

Darina Kodzahbasheva, Dr.

Ulrich Germing, Prof.

Stefanie Groepper, Dr.

Peter Reimer, Prof. Dr.

Swen Wessendorf, PD Dr.

Angela Krackhardt, Prof. Dr.

Hans Günter Derigs, Prof. Dr. med.

Michael Lübbert, Prof. Dr.

Maisun Abu Samra, Dr.

Volker Runde, Prof. Dr. med.

Annamaria Brioli, Dr.

Martin Bommer, PD Dr.

Gerald Wulf, Prof. Dr.

Walter Fiedler, Prof. Dr.

Hans Salwender, Dr.

Ahmet Elmaagacli, Prof.

Alexander Baraniskin, Dr.

Huesameddin Yildirim, Dr.

Daniela Doerfel, Dr.

Felicitas Thol, PD Dr.

Uwe Martens, Prof. Dr.

Dirk Strumberg, Prof. Dr.

Joerg Bittingbring, Dr.

Gerhard Held, Prof.

Martin Bentz, Prof. Dr.

Martina Gnadler

Ali Nuri Hünerlitürkoglu, Dr.

Christian Bogner, Dr.

Stephan Kremers, Dr. med.

Frank Hartmann, Prof. Dr. med.

Martin Hoffmann, Dr.

Friederike Wortmann, Dr.

Monika Schwalenberg, Dr.

Ana Maria Waldleben

Christian Plate, Dr.

Michael Kuehn, Dr.

Mohammad Wattad, Dr.

Hans-Joachim Tischler, Dr.

Holger Hebart, Prof. Dr. med.

Jan Schröder, Dr.

Katharina Götze, Prof. Dr.

Thomas Wehler

Irmgard Dresel, Dr.

Frank Griesinger, Prof. Dr.

Andreas Voss, Dr.

Thomas Südhoff, Prof. Dr.

Su Hyeon Kim, Dr.

Michael Klein, Dr.

Hendrik Poeck, Prof. Dr.

Julian Alexis Topaly

Stephan Kremers, Dr.

Detlev Kohl, Dr

Jan Schleicher, Dr. med.

Jochen Greiner, Prof. Dr.

Claudio Denzlinger, Prof. Dr.

Thomas Kubin, Dr. med.

Rolf Mahlberg, Dr. med.

Iordanis Deligiannis, Dr.

Claudia Lengerke, Prof.

Konstanze Döhner, Prof. Dr.

Paul Graf La Rosee, Prof. Dr.

Heiko Hütten

Silke Schostok, Dr.

This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms

Investigator's sites: 60-70 sites in Germany and Austria

Estimated duration of observation of an individual patient:

10 years maximum

Objectives

* To register all patients with acute myeloid leukemia and related precursor neoplasms, acute leukemia of unambiguous lineage, with higher risk myelodysplastic syndromes (MDS with excess blasts 2), and with myeloid neoplasms with germline predisposition, newly diagnosed or relapsed/refractory in all participating centers (completeness)
* To perform timely analyses of disease-related genetic markers (incidences, treatment recommendations)
* To assess patient and family history, clinical characteristics and outcome data (event-free survival \[EFS\], cumulative incidence of relapse \[CIR\], cumulative incidence of death \[CID\], overall survival \[OS\])
* To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers)
* To store biosamples from all patients (e.g., bone marrow, blood, plasma, normal tissue, e.g., skin biopsy, buccal swap, finger nails, hairs, or sputum)
* To assess quality of life

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project

To perform timely analyses of disease-related genetic markers (according to WHO 2008 classification) (incidences, treatment recommendations)

To assess patient and family history, patient characteristics and outcome data (event-free survival \[EFS\], cumulative incidence of relapse \[CIR\], cumulative incidence of death \[CID\], overall survival \[OS\])

Quality of life assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, socioeconomics, and demographics according to Messerer D et al (2008) initially, in first CR, one year, 3 and 5 years after initial diagnosis.

Geographical representation of patients through collection of patients zip codes

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID)	NCT05541380	Thyroid Cancer	A Taiwanese Onc...	20 Years -	National Health Research Institutes, Taiwan
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland	NCT05701007	Metastatic Cast... Metastatic Cast...	abiraterone enzalutamide docetaxel apalutamide cabazitaxel Radium-223 Lutetium-177 degarelix goserelin leuprorelin triptorelin	18 Years -	Pfizer
A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients (TOPICS-THYROID)	NCT05541380	Thyroid Cancer	A Taiwanese Onc...	20 Years -	National Health Research Institutes, Taiwan
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project	NCT01252485	Acute Myeloid L... Higher Risk Mye...		18 Years -	University of Ulm
International Rare Histiocytic Disorders Registry (IRHDR)	NCT02285582	Rare Histiocyti... Juvenile Xantho... Reticulohistioc... Xanthoma Dissem... Multicentric Re... Systemic Juveni... Erdheim-Chester... Multi-system Ro...	Registry study	-	The Hospital for Sick Children
Registry Study on Biological Disease Profile and Clinical Outcome in Patients With Newly Diagnosed or Existent Lung Cancer The LuCa Biology and Outcome (BiO)-Project	NCT02613637	Lung Cancer	Registry	18 Years -	University of Ulm
German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)	NCT03125707	BCR-ABL1-Negati...	Registry study	18 Years -	University of Ulm

Spots Global Cancer Trial Database for registry study